0 0 0 -0.0029390681003584 -0.0029390681003584 -0.0029390681003584 -0.0029390681003584 -0.0029390681003584
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences ( NASDAQ:GILD ) shares were unchanged in premarket after the company agreed to acquire autoimmune biotech Ouro Medicines for up to $2.2 billion, including roughly $1.7 billion upfront and $500 million in milestone payments, as it ramps up dealmaking following a period of relative inactivity. The move comes shortly after its $7.8 billion acquisition of Arcellx. The deal adds an early-stage T-cell engager therapy targeting autoimmune diseases, described by analysts as a pipeline-in-a-product opportunity with potential applications across multiple conditions. Ouro's lead drug is currently being tested across four autoimmune indications and may also extend into oncology, broadening its strategic relevance. The acquisition pushes Gilead, best known for HIV franchises such as Biktarvy, further into autoimmune disease, expanding beyond its core therapeutic focus. Shares have risen 28% over the past year, supporting a market value of about $170 billion. Recommended Stor [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences ( NASDAQ:GILD ) shares were unchanged in premarket after the company agreed to acquire autoimmune biotech Ouro Medicines for up to $2.2 billion, including roughly $1.7 billion upfront and $500 million in milestone payments, as it ramps up dealmaking following a period of relative inactivity. The move comes shortly after its $7.8 billion acquisition of Arcellx. The deal adds an early-stage T-cell engager therapy targeting autoimmune diseases, described by analysts as a pipeline-in-a-product opportunity with potential applications across multiple conditions. Ouro's lead drug is currently being tested across four autoimmune indications and may also extend into oncology, broadening its strategic relevance. The acquisition pushes Gilead, best known for HIV franchises such as Biktarvy, further into autoimmune disease, expanding beyond its core therapeutic focus. Shares have risen 28% over the past year, supporting a market value of about $170 billion. Recommended Stor [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS